US equities
|
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Tenpoint Therapeutics, Ltd.
Tenpoint Therapeutics Announces New Drug Submission to Health Canada for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults
November 20, 2026
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics Launches the YUVEZZI™ Telehealth Prescribing Program
November 09, 2026
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics to Participate in Upcoming Investor Conferences and Medical Meetings
September 09, 2026
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics Announces United Kingdom YUVEZZI™ Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults
July 13, 2026
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics Launches YUVEZZI™ Direct-to-Consumer Campaign Featuring a Cast of Hand-Crafted Puppets Giving a Voice to the Everyday Fusses of Blurry Close-Up Vision
June 29, 2026
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics, Ltd. Appoints Stephen S. Lane, M.D., as Chief Medical Officer
April 07, 2026
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI™
January 28, 2026
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
January 28, 2026
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics, Ltd. to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
December 16, 2025
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics Ltd. Announces Submission of a New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia to the MFDS in South Korea
November 05, 2025
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics, Ltd. to Participate in Four Upcoming Investor Conferences
October 13, 2025
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics, Ltd. to Participate in Upcoming Eye Care Conferences
September 08, 2025
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics Ltd. to Participate in Upcoming Investor Conferences in August
August 04, 2025
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics Ltd. to Participate in Virtual Presbyopia Panel Hosted by JonesTrading
July 22, 2025
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics Ltd. Announces FDA Acceptance of New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia
June 03, 2025
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics Ltd. Appoints Melissa Epperly as Chief Financial Officer
June 02, 2025
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics Ltd. to Participate at Citi Biotech Private Access Day
April 23, 2025
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics Ltd. Submits New Drug Application to U.S. FDA for BRIMOCHOL™ PF for the Treatment of Presbyopia
April 08, 2025
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire
Tenpoint Therapeutics Ltd. to Participate in Upcoming Investor Conferences in April
March 31, 2025
From
Tenpoint Therapeutics, Ltd.
Via
Business Wire